Sareum
Holdings plc
("Sareum" or the
"Company")
US patent allowance for its lead
programme SDC-1801
- Notice of Allowance from US
Patent and Trademark Office received
Cambridge, UK,
2 September 2024 - Sareum Holdings plc (AIM:
SAR), a clinical-stage biotechnology company developing
next-generation kinase inhibitors for autoimmune disease and
cancer, is pleased to announce that it has received a Notice of
Allowance from the US Patent and Trademark Office
(USPTO) for a patent on SDC-1801, a dual TYK2/JAK1 kinase
inhibitor being developed as a potential new therapeutic
for a range of autoimmune diseases.
The US patent, application number US2021387981,
will offer substantial protection on the chemical structure of
SDC-1801 and an analogue, their use in treating inflammatory
diseases and in certain methods of their chemical
synthesis.
Sareum has now secured patent coverage in the
major territories, following patent approvals by the European
Patent Office, China National Intellectual Property Administration
and Japan Patent Office for the same protections. The Company
expects the US patent to be granted by the end of 2024, subject to
the fulfilment of certain formalities with the USPTO.
Dr John
Reader, Sareum's Chief Scientific Officer,
commented: "We are pleased to extend the patent
protection for SDC-1801 on the back of the encouraging data from
our Phase 1a trial, indicating our inhibitor could confer
significant advantages over other TYK2/JAK1 kinase inhibitors. We
remain motivated in progressing SDC-1801 through clinical
development to develop new therapeutics for autoimmune diseases and
cancers."
- Ends -
For further
information, please contact:
|
Sareum Holdings plc
Stephen Parker, Executive
Chairman
|
01223 497700
ir@sareum.co.uk
|
|
Strand Hanson Limited (Nominated
Adviser)
James Dance / James
Bellman
|
020 7409 3494
|
|
Hybridan LLP (Corporate
Broker)
Claire Noyce
|
020 3764 2341
|
|
ICR Consilium (Financial
PR)
Jessica Hodgson / Davide Salvi
/ Kumail
Waljee
|
0203 709 5700
|
About
Sareum
Sareum Holdings (AIM:SAR) is a
clinical-stage biotechnology company
developing next generation kinase inhibitors for autoimmune disease
and cancer.
The Company is focused on developing
next generation small molecules which modify the activity of the
JAK kinase family and have best-in-class potential. Its lead
candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1.
SDC-1801 is a potential treatment for a range of autoimmune
diseases and has entered Phase 1a/b clinical development with an
initial focus on psoriasis.
Sareum is also developing SDC-1802,
a TYK2/JAK1 inhibitor with a potential application for cancer
immunotherapy.
Sareum Holdings plc is based in
Cambridge, UK, and is listed on the AIM market of the London Stock
Exchange, trading under the ticker SAR. For further information,
please visit the Company's website at www.sareum.com